Parmax Pharma Board Meeting on Nov 13 to Approve Q2 FY27 Results

Parmax Pharma Ltd has announced that its Board of Directors will convene on November 13, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. The meeting will also address the shifting of the company's registered office. In line with SEBI regulations, the trading window for company securities will remain closed until 48 hours after the announcement of these financial results.